I-Mab (IMAB)

Market Cap	534.83M
Revenue (ttm)	n/a
Net Income (ttm)	-39.99M
Shares Out	115.27M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,664,990
Open	4.740
Previous Close	4.700
Day's Range	4.430 - 4.880
52-Week Range	0.595 - 6.790
Beta	1.46
Analysts	Strong Buy
Price Target	7.50 (+61.64%)
Earnings Date	Nov 14, 2025

About IMAB

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 17, 2020
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: IMAB
• Website: https://www.i-mabbiopharma.com

Analyst Summary

According to 6 analysts, the average rating for IMAB stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 61.64% from the latest price.

Price Target

$7.5

(61.64% upside)

Analyst Consensus: Strong Buy